Company Overview - Generate Biomedicines, a drug developer based in Somerville, Massachusetts, is targeting a valuation of up to $2.17 billion in its upcoming initial public offering (IPO) in the United States [1] - The company is backed by venture firm Flagship Pioneering and aims to raise up to $425 million by offering 25 million shares priced between $15 and $17 each [1] IPO Details - Generate Biomedicines plans to list on the Nasdaq under the symbol "GENB" [1] - The IPO comes as biotech offerings have seen a strong start this year, following a sluggish 2025, attributed to easing interest rates and increased capital inflows into the sector [1] Underwriters - The underwriters for the offering include Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities, and Cantor [1]
Generate Biomedicines aims to raise $425 million in US IPO